Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascaline Boudou-Rouquette

Showing results (81-90 of 122) with videos related to

Pageof 13
Sort By:
Cancer Chemotherapy and Pharmacology|April 1, 2017
Potential drug-drug interactions with abiraterone in metastatic castration-resistant prostate cancer patients: a prevalence study in FranceClément Bonnet, Pascaline Boudou-Rouquette, Esther Azoulay-Rutman, et al.
Cancer Treatment Reviews|September 22, 2023
A systematic review of recent phase-II trials in refractory or recurrent osteosarcoma: Can we inform future trial design?Roelof van Ewijk, Morgane Cleirec, Nikolas Herold, et al.
International Journal of Cancer|August 6, 2025
The Fibrosis-4 score is associated with overall mortality and severe haematological toxicity in older patients with cancer: Analysis of two prospective cohort studiesVictoire de Salins, Claudia Martinez-Tapia, Pierre Gay, et al.
Clinical Nutrition (Edinburgh, Scotland)|April 4, 2026
Resting energy expenditure as a predictor of immune checkpoint inhibitors response in older patients with non-small cell metastatic lung cancer: A pooled analysis of two prospective cohort studiesMarie Pautas, Pascaline Boudou-Rouquette, Anne Jouinot, et al.
The Oncologist|January 2, 2019
Depressive Symptom Profiles and Survival in Older Patients with Cancer: Latent Class Analysis of the ELCAPA Cohort StudyClément Gouraud, Elena Paillaud, Claudia Martinez-Tapia, et al.
Lung Cancer (Amsterdam, Netherlands)|May 21, 2022
SMARCA4-deficient lung carcinoma is an aggressive tumor highly infiltrated by FOXP3+ cells and neutrophilsYoan Velut, Elise Decroix, Hélène Blons, et al.
Bulletin Du Cancer|March 27, 2025
Chondrosarcomas: Multidisciplinary review and practical recommendations, on behalf of GroupOsPascaline Boudou-Rouquette, Nadège Corradini, Marie-Pierre Sunyach, et al.
Cancers|July 9, 2022
Association of Energy Expenditure and Efficacy in Metastatic Renal Cell Carcinoma Patients Treated with NivolumabJohanna Noel, Anne Jouinot, Jérôme Alexandre, et al.
Cancer Chemotherapy and Pharmacology|July 25, 2021
Prevalence of drug-drug interactions in sarcoma patients: key role of the pharmacist integration for toxicity risk managementAudrey Bellesoeur, Ithar Gataa, Anne Jouinot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2022
Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II StudyVivek Subbiah, Irene Braña, Alessandra Longhi, et al.
Pageof 13

Showing results (81-90 of 122) with videos related to

Sort By:
Pageof 13
Cancer Chemotherapy and Pharmacology|April 1, 2017
Potential drug-drug interactions with abiraterone in metastatic castration-resistant prostate cancer patients: a prevalence study in FranceClément Bonnet, Pascaline Boudou-Rouquette, Esther Azoulay-Rutman, et al.
Cancer Treatment Reviews|September 22, 2023
A systematic review of recent phase-II trials in refractory or recurrent osteosarcoma: Can we inform future trial design?Roelof van Ewijk, Morgane Cleirec, Nikolas Herold, et al.
International Journal of Cancer|August 6, 2025
The Fibrosis-4 score is associated with overall mortality and severe haematological toxicity in older patients with cancer: Analysis of two prospective cohort studiesVictoire de Salins, Claudia Martinez-Tapia, Pierre Gay, et al.
Clinical Nutrition (Edinburgh, Scotland)|April 4, 2026
Resting energy expenditure as a predictor of immune checkpoint inhibitors response in older patients with non-small cell metastatic lung cancer: A pooled analysis of two prospective cohort studiesMarie Pautas, Pascaline Boudou-Rouquette, Anne Jouinot, et al.
The Oncologist|January 2, 2019
Depressive Symptom Profiles and Survival in Older Patients with Cancer: Latent Class Analysis of the ELCAPA Cohort StudyClément Gouraud, Elena Paillaud, Claudia Martinez-Tapia, et al.
Lung Cancer (Amsterdam, Netherlands)|May 21, 2022
SMARCA4-deficient lung carcinoma is an aggressive tumor highly infiltrated by FOXP3+ cells and neutrophilsYoan Velut, Elise Decroix, Hélène Blons, et al.
Bulletin Du Cancer|March 27, 2025
Chondrosarcomas: Multidisciplinary review and practical recommendations, on behalf of GroupOsPascaline Boudou-Rouquette, Nadège Corradini, Marie-Pierre Sunyach, et al.
Cancers|July 9, 2022
Association of Energy Expenditure and Efficacy in Metastatic Renal Cell Carcinoma Patients Treated with NivolumabJohanna Noel, Anne Jouinot, Jérôme Alexandre, et al.
Cancer Chemotherapy and Pharmacology|July 25, 2021
Prevalence of drug-drug interactions in sarcoma patients: key role of the pharmacist integration for toxicity risk managementAudrey Bellesoeur, Ithar Gataa, Anne Jouinot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2022
Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II StudyVivek Subbiah, Irene Braña, Alessandra Longhi, et al.
Pageof 13